[1] YAGHI S，WILLEY J Z，CUCCHIARA B，et

al. Treatment and outcome of hemorrhagic

transformation after intravenous alteplase in acute

ischemic stroke：a scientific statement for healthcare

professionals from the American Heart Association/

American Stroke Association[J/OL]. Stroke，2017，

48（12）：e343-e361[2019-12-15]. https：//doi.

org/10.1161/STR.0000000000000152.

[2] TSIRKA S E，GUALANDRIS A，AMARAL D

G，et al. Excitotoxin-induced neuronal degeneration

and seizure are mediated by tissue plasminogen

activator[J]. Nature，1995，377（6547）：340-344.

[3] LIU D，CHENG T，GUO H，et al. tPA neurovascular

toxicity is controlled by activated protein C[J]. Nat

Med，2004，10（12）：1379-1383.

[4] CUADRADO E，ORTEGA L，HERNÁNDEZGUILLAMON

M，et al. Tissue plasminogen

activator（t-PA）promotes neutrophil degranulation

and MMP-9 release[J]. J Leukoc Biol，2008，84（1）：

207-214.

[5] LU G，HE Q，SHEN Y，et al. Potential biomarkers

for predicting hemorrhagic transformation of

ischemic stroke[J]. Int J Neurosci，2018，128（1）：

79-89.

[6] HARTMANN S，RIDLEY A J，LUTZ S. The

function of rho-associated kinases ROCK1 and

ROCK2 in the pathogenesis of cardiovascular

disease[J]. Front Pharmacol，2015，6（5）：276.

[7] JICKLING G C，LIU D，STAMOVA B，et al.

Hemorrhagic transformation after ischemic stroke in

animals and humans[J]. J Cereb Blood Flow Metab，

2014，34（2）：185-199.

[8] YAMAGUCHI T，AWANO H，MATSUDA H，et

al. Edaravone with and without. 6 mg/kg alteplase

within 4.5 hours after ischemic stroke：a prospective

cohort study（PROTECT 4.5）[J]. J Stroke

Cerebrovasc Dis，2017，26（4）：756-765.

[9] CAMPOS F，QIN T，CASTILLO J，et al. Fingolimod

reduces hemorrhagic transforma tion associated with

delayed tissue plasminogen activator treatment in a

mouse thromboembolic model[J]. Stroke，2013，44

（2）：505-511.

[10] ROGOVE A D，SIAO C，KEYT B，et al. Activation

of microglia reveals a non-proteolytic cytokine

function for tissue plasminogen activator in the

central nervous system[J]. J Cell Sci，1999，112（22）：

4007-4016.

[11] SHI Z S，DUCKWILER G R，JAHAN R，et al.

Early blood‐brain barrier disruption after mechanical

thrombectomy in acute ischemic stroke[J]. J

Neuroimaging，2018，28（3）：283-288.

[12] SHI Z S，LIEBESKIND D S，LOH Y，et al，

Predictors of subarachnoid hemorrhage in acute

ischemic stroke with endovascular therapy[J]. Stroke，

2010，41（12）：2775-2781.

[13] SAVER J L，GOYAL M，VAN DER LUGT A，et al.

Time to treatment with endovascular thrombectomy

and outcomes from ischemic stroke：a metaanalysis[

J]. JAMA，2016，316（12）：1279-1288.

[14] NOGUEIRA R G，JADHAV A P，HAUSSEN D C，

et al. Thrombectomy 6 to 24 hours after stroke with

a mismatch between deficit and infarct[J]. N Engl J

Med，2018，378（1）：11-21.

[15] ALBERS G W，MARKS M P，KEMP S，et al.

Thrombectomy for stroke at 6 to 16 hours with

selection by perfusion imaging[J]. N Engl J Med，

2018，378（8）：708-718.

[16] International Stroke Trial Collaborative Group. The

International Stroke Trial（IST）：a randomised

trial of aspirin，subcutaneous heparin，both，or

neither among 19 435 patients with acute ischaemic

stroke[J]. Lancet，1997，349（9065）：1569-1581.

[17] TSIVGOULIS G，KATSANOS A H，MAVRIDIS D，

et al. Intravenous thrombolysis for ischemic stroke

patients on dual antiplatelets[J]. Ann Neurol，2018，

84（1）：89-97.

[18] DIEDLER J，AHMED N，SYKORA M，et al. Safety

of intravenous thrombolysis for acute ischemic

stroke in patients receiving antiplatelet therapy at

stroke onset[J]. Stroke，2010，41（2）：288-294.

[19] LUO S，ZHUANG M，ZENG W，et al. Intravenous

thrombolysis for acute ischemic stroke in patients

receiving antiplatelet therapy：a systematic review

and meta-analysis of 19 studies[J/OL]. J Am Heart

Assoc，2016，5（5）：e003242[2019-12-15]. https：//

doi.org/10.1161/JAHA.116.003242.

[20] SA?ÁK D，KULIHA M，HERZIG R，et al. Prior

use of antiplatelet therapy can be associated with

a higher chance for early recanalization of the

occluded middle cerebral artery in acute stroke

patients treated with intravenous thrombolysis[J].

Eur Neurol，2012，67（1）：52-56.

[21] ZINKSTOK S M，ROOS Y B，ARTIS investigators.

Early administration of aspirin in patients treated

with alteplase for acute ischaemic stroke：a

randomised controlled trial[J]. Lancet，2012，380

（9843）：731-737.

[22] RESTART Collaboration. Effects of antiplatelet

therapy after stroke due to intracerebral haemorrhage

（RESTART）：a randomised，open-label trial[J].

Lancet，2019，393（10 191）：2613-2623.

[23] WHITELEY W N，SLOT K B，FERNANDES P，et

a1. Risk factors for intracranial hemorrhage in acute

ischemic stroke patients treated with recombinant

tissue plasminogen activator：a systematic review

and meta-analysis of 55 studies[J]. Stroke，2012，43

（111）：2904-2909.

[24] 中华医学会神经病学分会与中华医学会神经病学分

会脑血管病学组. 中国急性脑梗死后出血转化诊治

共识2019[J]. 中华神经科杂志，2019，52（4）：252-

265.

[25] KUDO K，SASAKI M，YAMADA K，et al.

Differences in CT perfusion maps generated by

different commercial software：quantitative analysis

by using identical source data of acute stroke

patients[J]. Radiology，2010，254（1）：200-209.

[26] YASSI N，PARSONS M W，CHRISTENSEN

S，et al. Prediction of poststroke hemorrhagic

transformation using computed tomography

perfusion[J]. Stroke，2013，44（11）：3039-3043.

[27] SHI F，GONG X，LIU C，et al. Acute stroke：

prognostic value of quantitative collateral assessment

at perfusion CT[J]. Radiology，2019，290（3）：760-

768.

[28] EL NAWAR R，YEUNG J，LABREUCHE J，et al.

MRI-based predictors of hemorrhagic transformation inpatients with stroke treated by intravenous

thrombolysis[J]. Front Neurol，2019，10（6）：897.

[29] SCALZO F，ALGER J R，HU X，et a1. Multicenter

prediction of hemorrhagic transformation in

acute ischemic stroke using permeability imaging

features[J]. Magn Reson Imaging，2013，31（6）：

961-969.

[30] CAMPBELL B C，CHRISTENSEN S，BUTCHER

K S，et a1. Regional very low cerebral blood volume

predicts hemorrhagic transformation better than

diffusion-weighted imaging volume and thresholded

apparent diffusion coefficient in acute ischemic

stroke[J]. Stroke，2010，41（1）：82-88.

[31] CHARIDIMOU A，SHOAMANESH A，

International META-MICROBLEEDS Initiative.

Clinical relevance of microbleeds in acute stroke

thrombolysis[J]. Neurology，2016，87（15）：1534-

1541.

[32] TURC G，SALLEM A，MOULIN S，et al.

Microbleed status and 3-month outcome after

intravenous thrombolysis in 717 patients with acute

ischemic stroke[J]. Stroke，2015，46（9）：2458-2463.

[33] KELLY P J，MORROW J D，NING M，et al.

Oxidative stress and matrix metalloproteinase-9 in

acute ischemic stroke：the Biomarker Evaluation

for Antioxidant Therapies in Stroke（BEAT-Stroke）

study[J]. Stroke，2008，39（1）：100-104.

[34] TURNER R J，SHARP F R. Implications of MMP9

for blood brain barrier disruption and hemorrhagic

transformation following ischemic stroke[J]. Front

Cell Neurosci，2016，10（6）：56.

[35] FOERCH C，WUNDERLICH M T，DVORAK

F，et al. Elevated serum S100B levels indicate a

higher risk of hemorrhagic transformation after

thrombolytic therapy in acute stroke[J]. Stroke，2007，

38（9）：2491-2495.

[36] LUGER S，WITSCH J，DIETZ A，et al. Glial

fibrillary acidic protein serum levels distinguish

between intracerebral hemorrhage and cerebral

ischemia in the early phase of stroke[J]. Clin Chem，

2017，63（1）：377-385.

[37] MAESTRINI I，STRBIAN D，GAUTIER S，et

al. Higher neutrophil counts before thrombolysis

for cerebral ischemia predict worse outcomes[J].

Neurology，2015，85（16）：1408-1416.

[38] LEE J H，PARK K Y，SHIN J H，et al. Symptomatic

hemorrhagic transformation and its predictors in

acute ischemic stroke with atrial fibrillation[J]. Eur

Neurol，2010，64（4）：193-200.

[39] GORI A M，GIUSTI B，PICCARDI B，et al.

Inflammatory and metalloproteinases profiles predict

three-month poor outcomes in ischemic stroke

treated with thrombolysis[J]. J Cereb Blood Flow

Metab，2017，37（9）：3253-3261.

[40] KANAZAWA M，IGARASHI H，KAWAMURA

K，et al. Inhibition of VEGF signaling pathway

attenuates hemorrhage after tPA treatment[J]. J

Cereb Blood Flow Metab，2011，31（6）：1461-1474.

[41] SOBRINO T，MILLAN M，CASTELLANOS M，

et al. Association of growth factors with arterial

recanalization and clinical outcome in patients

with ischemic stroke treated with tPA[J]. J Thromb

Haemost，2010，8（7）：1567-1574.

[42] RODRIGUEZ-YANEZ M，CASTELLANOS M，

BLANCO M，et al. Micro and macroalbuminuria

predict hemorrhagic transformation in acute

ischemic stroke[J]. Neurology，2006，67（7）：1172-

1177.

[43] KASE C S，FURLAN A J，WECHSLER L R，

et al. Cerebral hemorrhage after intra-arterial

thrombolysis for ischemic stroke：the PROACT Ⅱ

trial[J]. Neurology，2001，57（9）：1603-1610.

[44] LEE J H，PARK K Y，SHIN J H，et al. Symptomatic

hemorrhagic transformation and its predictors in

acute ischemic stroke with atrial fibrillation[J]. Eur

Neurol，2010，64（4）：193-200.

[45] YANG N，LIN M，WANG B G，et al. Low level

of low-density lipoprotein cholesterol is related

with increased hemorrhagic transformation after

acute ischemic cerebral infarction[J]. Eur Rev Med

Pharmacol Sci，2016，20（4）：673-678.

[46] LIU，J，WANG D，XIONG Y，et al. Low free

triiodothyronine levels are related to symptomatic

intracranial hemorrhage and poor functional

outcomes after intravenous thrombolysis in acute

ischemic stroke patients[J]. Neurol Res，2016，38（5）：

429-433.